Eupraxia Pharmaceuticals Inc (EPRX) - News Archive

Eupraxia Pharmaceuticals Progress in EoE Treatment: Eupraxia Pharmaceuticals has reported encouraging 52-week follow-up results from their RESOLVE clinical trial, focusing on their investigational therapy, EP-104GI, for...

VICTORIA, BC, April 11, 2024 - Eupraxia Pharmaceuticals Inc. (Eupraxia or the Company) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere technology to optimize dru...